Research programme: BRAF kinase inhibitors - Amgen
Latest Information Update: 16 Jul 2016
At a glance
- Originator Amgen
- Class
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 21 Apr 2010 Preclinical trials in Cancer in USA (PO)
- 21 Apr 2010 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)